Type Private Website www.merz.com Headquarters Frankfurt Parent organization Merz GmbH & Co. KGaA | Industry Pharmaceuticals Number of employees 2,754 Founded 9 March 1908 | |
 | ||
Key people Andreas Krebs, Chairman, Philip Burchard, Chief Executive Officer Products Xeomin, Mederma, Solvex CEO Philip Burchard (1 Jul 2012–) Revenue 1.157 billion EUR (2014–2015) Subsidiaries Merz Pharmaceuticals GmbH, MERZ NORTH AMERICA, INC., Anteis S.A., Merz Pharma GmbH | ||
Merz pharmaceuticals corporate film
Merz Pharma GmbH & Co. KGaA is an international healthcare company specializing in over-the-counter and prescription creams, ointments and injectables in the fields of dermatology, neurology and metabolic disorders. Based in Frankfurt am Main, Germany, Merz is a leader in the field of Alzheimer's disease research and developed memantine as the first drug for the treatment of moderate to severe Alzheimer's disease. Other franchises covered by Merz are hepatology / metabolic diseases and dermatology (including Mederma scar gel). In Asia Pacific, the Merz franchise covers aesthetic dermatology (including Radiesse and Xeomin).
Contents
- Merz pharmaceuticals corporate film
- New dermal fillers cellulite treatments and skincare products from merz pharmaceuticals
- History
- References
Merz was founded in 1908, has over 2700 employees and had 994 million euros of sales in 2013-14. The US subsidiary of Merz is Merz Pharmaceuticals LLC which was located in Greensboro, North Carolina. However, Merz has recently decided to move to Raleigh, North Carolina.
Merz Pharma is considered to be a leader in the aesthetics, dermatology and neurosciences markets and it consolidated its position by the $600 million purchase of niche aesthetics medical device maker, Ulthera.
New dermal fillers cellulite treatments and skincare products from merz pharmaceuticals
History
Merz Pharma GmbH & Co. KGaA was founded in 1908 by Friedrich Merz, a pharmacist by training. In 1909, the company moved to a new location at Eckenheimer Landstraße.